Therapy development inspired by patients

Top-line results from Phase III ADORE study in ALS

In reference to the official press release of our pharma partner Ferrer, we regret to share that the top-line results of the phase 3 clinical study ADORE* show that the primary or key secondary endpoints were not met. In the ADORE study, our lead product TW001 (FAB122...

Phase III clinical trial TW001/FNP122 for ALS, partnered with Ferrer

With the licensing agreement between Treeway and Ferrer in place, FNP122 (formerly TW001) has now entered clinical stage phase III with the initiation of the ADORE study (ALS Deceleration study with Oral Edaravone). In a large-scale double-blind placebo-controlled...

Rare Disease Symposium April 18th

On Thursday April 18, Treeway’s CEO Inez de Greef is a speaker at the Rare Diseases Symposium. The second edition of the Rare Disease Symposium, organized by HollandBIO, is about challenging the status quo and the development of orphan drugs. Inez will talk about...

Australian Motor Neurone Disease Symposium

This week, the Australian Motor Neurone Disease Symposium takes place in Melbourne, Australia. Our CEO, Inez de Greef-van der Sandt, will present the clinical development of TW001 by Treeway...

ALS SYMPOSIUM: Samen tegen ALS. Samen voor de patiënt.

Op maandag 9 april wordt in samenwerking met het Jeroen Bosch Ziekenhuis een maatschappelijk symposium georganiseerd rondom het thema ALS. Vanuit drie invalshoeken zal het thema worden geduid. Inez de Greef, CEO van Treeway, zal spreken over de zoektocht naar een...